La Jolla Pharmaceutical Co Stock as Institutional Investors Exit

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Logo

Sentiment for La Jolla Pharmaceutical Co (NASDAQ:LJPC)

La Jolla Pharmaceutical Co (NASDAQ:LJPC) institutional sentiment decreased to 1.23 in Q3 2018. Its down -0.27, from 1.5 in 2018Q2. The ratio turned negative, as 38 institutional investors increased and started new holdings, while 31 sold and reduced stock positions in La Jolla Pharmaceutical Co. The institutional investors in our partner’s database now own: 32.70 million shares, up from 30.09 million shares in 2018Q2. Also, the number of institutional investors holding La Jolla Pharmaceutical Co in their top 10 holdings was flat from 4 to 4 for the same number . Sold All: 15 Reduced: 16 Increased: 28 New Position: 10.

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company has market cap of $170.54 million. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. It currently has negative earnings. The firm is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

The stock decreased 0.75% or $0.05 during the last trading session, reaching $6.5. About 841,149 shares traded or 8.82% up from the average. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has declined 56.94% since January 14, 2018 and is downtrending. It has underperformed by 56.94% the S&P500.

Analysts await La Jolla Pharmaceutical Company (NASDAQ:LJPC) to report earnings on February, 28. They expect $-1.82 EPS, down 4.60 % or $0.08 from last year’s $-1.74 per share. After $-1.93 actual EPS reported by La Jolla Pharmaceutical Company for the previous quarter, Wall Street now forecasts -5.70 % EPS growth.

Tang Capital Management Llc holds 13.6% of its portfolio in La Jolla Pharmaceutical Company for 4.14 million shares. Broadfin Capital Llc owns 2.05 million shares or 6.08% of their US portfolio. Moreover, Sectoral Asset Management Inc has 3.52% invested in the company for 1.65 million shares. The New York-based Perceptive Advisors Llc has invested 2.32% in the stock. Emory University, a Georgia-based fund reported 117,476 shares.

Since January 1, 0001, it had 6 insider purchases, and 1 sale for $4.64 million activity.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage

Ratings analysis reveals 0 of La Jolla Pharmaceutical’s analysts are positive. Out of 2 Wall Street analysts rating La Jolla Pharmaceutical, 0 give it “Buy”, 2 “Sell” rating, while 0 recommend “Hold”. The lowest target is $21 while the high is $22. The stock’s average target of $21.50 is 230.77% above today’s ($6.5) share price. LJPC was included in 2 notes of analysts from August 9, 2018. As per Thursday, August 9, the company rating was maintained by Jefferies. On Friday, August 10 the stock rating was maintained by JP Morgan with “Underweight”.

More important recent La Jolla Pharmaceutical Company (NASDAQ:LJPC) news were published by: which released: “The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial – Yahoo! Finance News” on December 21, 2018, also published article titled: “58 Biggest Movers From Yesterday – Benzinga”, published: “10 Biggest Price Target Changes For Monday – Benzinga” on January 14, 2019. More interesting news about La Jolla Pharmaceutical Company (NASDAQ:LJPC) was released by: and their article: “Stocks To Watch: CES Headlines Action-Packed Week – Seeking Alpha” with publication date: January 05, 2019.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.